Indolent B-Cell Lymphoma
Indolent B-Cell Lymphoma
The latest news, research, and perspectives in indolent B-cell lymphoma. This diverse group of slow-growing non-Hodgkin lymphomas form in B cells and include follicular lymphoma, hairy cell leukemia, and marginal zone lymphoma.
Leah SherwoodMyeloma | December 1, 2022
At Blood Cancers Today, we have compiled the year's top content awards as doled out by the Twitterverse. 
Read More
Leah SherwoodPrint | November 23, 2022
Manali Kamdar, MD; and Craig S. Sauter, MD, FACP; debate CAR T-cell therapy and AHSCT in second-line DLBCL.
Cecilia BrownIndolent B-Cell Lymphoma | November 15, 2022
Patients with LBCL received prophylactic anakinra to reduce the risk of cytokine release syndrome following CAR-T.
Leah SherwoodIndolent B-Cell Lymphoma | October 12, 2022
Orelabrutinib monotherapy may be an option for relapsed/refractory Waldenström’s macroglobulinemia.
Leah LawrenceIndolent B-Cell Lymphoma | June 23, 2022
Eighty percent of patients with marginal zone lymphoma (MZL) experienced tumor response with zanubrutinib monotherapy, ...
Leah LawrenceIndolent B-Cell Lymphoma | June 8, 2022
Umbralisib was approved to treat marginal zone lymphoma (MZL) and follicular lymphoma (FL).
Leah LawrenceIndolent B-Cell Lymphoma | June 8, 2022
The U.S. Food and Drug Administration (FDA) has granted tisagenlecleucel accelerated approval for adult patients with ...
Leah LawrenceIndolent B-Cell Lymphoma | May 31, 2022
The regimen improved overall survival in patients with MYC-translocated lymphomas.
Leah LawrenceTransplantation & Cellular Therapy | March 2, 2022
With increasing evidence of efficacy as front-line treatment in relapsed/refractory disease, clinicians are excited to see ...
Ariel DeMaioAggressive B-Cell Lymphoma | March 2, 2022
Pivotal trials that supported FDA approval of CAR T-cell therapies had low proportions of Black patients enrolled.
Sabrina AhleIndolent B-Cell Lymphoma | March 2, 2022
After failing to complete the requisite confirmatory trials following accelerated approval, Gilead has announced it will ...
Sabrina AhleIndolent B-Cell Lymphoma | March 2, 2022
Allogene Therapeutics has been cleared by the U.S. Food and Drug Administration (FDA) to resume trials of its allogeneic ...
Sabrina AhleIndolent B-Cell Lymphoma | February 25, 2022
FDA officials have expressed concerns about the quality of China-based clinical trials of cancer drugs, questioning whether ...
Sabrina AhleMyeloma | February 22, 2022
Patients with hematologic malignancies have a significantly higher rate of composite thrombotic outcomes during acute ...
Sabrina AhleAcute Lymphoblastic Leukemia | February 8, 2022
Researchers have discovered that chemotherapy and COVID-19 infection cause neuro-inflammation in similar ways.
Sabrina AhleChronic Lymphocytic Leukemia | February 7, 2022
The FDA has placed a partial clinical hold on trials evaluating umbralisib and ublituximab for the treatment of chronic ...
Sagar Lonial, MD, FACPMyeloma | February 2, 2022
Editor-in-Chief Sagar Lonial, MD, FACP, introduces the new publication from SOHO.
Susan O'Brien, MDAcute Lymphoblastic Leukemia | February 1, 2022
At SOHO 2021, Susan O'Brien, MD, and Hagop Kantarjian, MD, addressed trends in hematologic malignancies.
Kami Maddocks, MDAggressive B-Cell Lymphoma | January 20, 2022
Dr. Maddocks reflects on her small-town upbringing and learning to love triathlons.
Sabrina AhleIndolent B-Cell Lymphoma | January 8, 2022
The combination therapy was associated with increases in PFS rate and MRD negativity.
Advertisement
Editorial Board

Advertisement